Patients with systemic lupus erythematosus (SLE) often suffer from depression and fatigue in addition to the physical manifestations of the autoimmune disease. Elevated production of type-I interferons (IFN-I) has been found in lupus patients and IFN-I can precipitate a variety of neuropsychiatric side effects. This study was conducted to evaluate the relationship between dysregulated IFN-I production and the presence of depression or fatigue in lupus patients. Through cross-sectional and longitudinal analysis we found no significant correlation between abnormal IFN-I levels (as measured by peripheral blood expression of IFN-Istimulated genes) and neuropsychiatric manifestations. Elevation of endogenous serum IFN-I levels is unlikely to account for the depression and fatigue associated with SLE.
Introduction
Systemic lupus erythematosus (SLE) is a debilitating condition affecting multiple organ systems including the skin, kidneys, liver, heart, lungs, and nervous system (Reeves et al., 2004) . In addition to the autoimmune manifestations, more than half of patients with SLE suffer from depression and fatigue (Krupp et al., 1990; Shortall et al., 1995) . Interestingly, although SLE is characterized by cycles of disease flare and remission, the prevalence of depression and fatigue is not adequately explained by disease activity or other disease related variables (Gladman et al., 1996; Jump et al., 2005; Wang et al., 1998) . It remains uncertain whether these neuropsychiatric symptoms are due to the burden of having a chronic illness or other factors.
Recent studies suggest that type-I interferons (IFN-I) may play an essential role in the etiology of SLE (Lee and Reeves, 2006) . Several groups have demonstrated that more than half of SLE patients exhibit high serum levels of IFN-I and over-express a group of IFN-I-stimulated genes (ISGs) in their peripheral blood cells (Baechler et al., 2003; Bennett et al., 2003) . The presence of this interferon signature is associated with active disease, the presence of certain autoantibodies, and an increased incidence of renal involvement (Feng et al., 2006; Kirou et al., 2005; Zhuang et al., 2005) .
IFN-I are a family of anti-viral cytokines that includes IFN-β and all subtypes of IFN-α. Produced endogenously by the body in response to viral infection, IFN-I possess a number of immunostimulatory and anti-proliferative functions (Pestka et al., 2004) . These properties provide a rationale for using recombinant IFN-I to treat viral infection (e.g. hepatitis C) and certain malignancies (e.g. carcinoid syndrome) (Veenhof et al., 1992; Weimar et al., 1980) . Interestingly, IFN-I treatment also can modulate the levels of other cytokines, chemokines and neurotransmitters within the CNS (Raison et al., 2009a) . Therapeutic use of IFN-α induces neuropsychiatric side effects including psychosis, fatigue, and depression in patients without any history of psychiatric findings (Dieperink et al., 2000; Schaefer et al., 2002) . Due to the increased risk for suicidal ideation, IFN-α therapy is contraindicated in patients with depression (Dieperink et al., 2004; Janssen et al., 1994) .
Based on the psychiatric side effects of IFN-I therapy, we hypothesized that elevated serum levels of IFN-I might contribute to the neuropsychiatric manifestations of SLE. In this study, we evaluated the relationship between dysregulated IFN-I production and the presence of depression or fatigue in lupus patients.
Materials and methods

Study subjects
Fifty-eight patients meeting the American College of Rheumatology classification criteria for SLE (Tan et al., 1982) were recruited from Journal of Neuroimmunology 223 (2010) 13-19 
